Analytik Jena Acquires California-Based UVP
By LabMedica International staff writers Posted on 30 Apr 2013 |
Analytik Jena, AG (Jena, Germany) recently acquired all of the outstanding shares of UVP, LLC (Upland, CA, USA), including its subsidiary, Ultra-Violet Products, Ltd. (Cambridge UK).
UVP is a leading manufacturer of bioimaging systems for applications in proteomics, genomics, animal and plant sciences. The company also develops ultraviolet (UV) products, light sources, and laboratory equipment such as hybridization ovens, transilluminators, crosslinkers, and polymerase chain reaction (PCR) hoods.
The acquisition of UVP allows Analytik Jena to strengthen its presence in the US market and expand its product range. “With the acquisition of UVP, we are significantly expanding our business activities in the Life Science unit and are laying an excellent basis for developing our successful business model in the US and neighboring regions. Here, we are combining efficient sales structures, a well-coordinated product portfolio, and broad technological expertise in the respective core segments. Further extensive synergies are to arise, especially in sales in Europe and Asia. With UVP, Analytik Jena also gains a production plant in the US dollar currency area,” remarked Klaus Berka, CEO of Analytik Jena, AG.
Analytik Jena is a provider of analytic technology, life-science systems for bioanalytic applications, and high-end optical consumer products. With UVP’s incorporation into Analytik Jena’s life-science business unit, many synergies are expected.
According to Leighton Smith, UVP’s president and CEO, “UVP has an opportunity to contribute significantly to the growth and profitability of Analytik Jena’s Life Science business unit. Our combined manufacturing expertise, portfolio of products and distribution channels open up new market opportunities, and begins an exciting new chapter in UVP’s history of providing innovative products and solutions to our customers.”
Related Links:
Analytik Jena
UVP
UVP is a leading manufacturer of bioimaging systems for applications in proteomics, genomics, animal and plant sciences. The company also develops ultraviolet (UV) products, light sources, and laboratory equipment such as hybridization ovens, transilluminators, crosslinkers, and polymerase chain reaction (PCR) hoods.
The acquisition of UVP allows Analytik Jena to strengthen its presence in the US market and expand its product range. “With the acquisition of UVP, we are significantly expanding our business activities in the Life Science unit and are laying an excellent basis for developing our successful business model in the US and neighboring regions. Here, we are combining efficient sales structures, a well-coordinated product portfolio, and broad technological expertise in the respective core segments. Further extensive synergies are to arise, especially in sales in Europe and Asia. With UVP, Analytik Jena also gains a production plant in the US dollar currency area,” remarked Klaus Berka, CEO of Analytik Jena, AG.
Analytik Jena is a provider of analytic technology, life-science systems for bioanalytic applications, and high-end optical consumer products. With UVP’s incorporation into Analytik Jena’s life-science business unit, many synergies are expected.
According to Leighton Smith, UVP’s president and CEO, “UVP has an opportunity to contribute significantly to the growth and profitability of Analytik Jena’s Life Science business unit. Our combined manufacturing expertise, portfolio of products and distribution channels open up new market opportunities, and begins an exciting new chapter in UVP’s history of providing innovative products and solutions to our customers.”
Related Links:
Analytik Jena
UVP
Latest BioResearch News
- Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
- Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
- New Method Simplifies Preparation of Tumor Genomic DNA Libraries
- New Tool Developed for Diagnosis of Chronic HBV Infection
- Panel of Genetic Loci Accurately Predicts Risk of Developing Gout
- Disrupted TGFB Signaling Linked to Increased Cancer-Related Bacteria
- Gene Fusion Protein Proposed as Prostate Cancer Biomarker
- NIV Test to Diagnose and Monitor Vascular Complications in Diabetes
- Semen Exosome MicroRNA Proves Biomarker for Prostate Cancer
- Genetic Loci Link Plasma Lipid Levels to CVD Risk
- Newly Identified Gene Network Aids in Early Diagnosis of Autism Spectrum Disorder
- Link Confirmed between Living in Poverty and Developing Diseases
- Genomic Study Identifies Kidney Disease Loci in Type I Diabetes Patients
- Liquid Biopsy More Effective for Analyzing Tumor Drug Resistance Mutations
- New Liquid Biopsy Assay Reveals Host-Pathogen Interactions
- Method Developed for Enriching Trophoblast Population in Samples